Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019)
J

Plasmablastic Lymphoma: Survival Analysis of a SEER Database (2010-2016) - Demographic / Clinical Characteristics, OS and Lymphoma-Specific / HIV-Specific Survival

By Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019) FEATURING Jorge Florindez
By Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019) FEATURING Jorge Florindez
23 views
October 18, 2019
0 Comments
Login to view comments. Click here to Login

Featured Video

06:51
Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "Prevalence and Prediction of Ruxolitinib Tr…

Feat. D. Tremblay

Featured Video

15:14
Icahn School of Medicine at Mount Sinai

Safety Profile of Ruxolitinib in Patients With MF

Feat. D. Tremblay

Related Content

AUTOPLAY
08:18
Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "Treatment Strategies for Hematocrit Control…

Feat. A. Zhou
09:27
ASH 2022 Conference Coverage

MAJIC-PV Trial: Ruxolitinib vs. Best Available Therapy for PV Intole…

Feat. M. McMullin
17:21
Daniel Addison

Cardiovascular Considerations With (Contemporary) BTKi in the Treatm…

05:38
GRACE

Epcoritamab in NHL - Incidence and Management of CRS

Feat. T. Phillips
16:25
Northwestern Medicine Oncology and Hematology

Diagnosis and Goals of Therapy in PV

Feat. B. Stein
26:58
Total Health

Update on Cellular Therapy in Lymphoma

Feat. B. Randolph
33:11
Total Health

Bispecific Antibodies and CAR T-Cells for NHL: Challenges and Opport…

Feat. K. Komanduri
10:49
Monia Marchetti

Using Cytoreductive Therapy to Prevent Cardiovascular Events in Pati…

42:09
University of Colorado Department of Medicine

Immunotherapy in Lymphomas: The Present and the Future

Feat. M. Kamdar
06:38
Insights from 2023 ASCO® Annual Meeting

ASCO® 2023 Insights: "Updated Results From EPCORE NHL-1 - Effec…

Feat. Y. Karimi
13:04
Winship Cancer Institute - Emory University

Treatment-Related Quality of Life in MF

Feat. A. Hunter
08:02
ASH 2022 Conference Coverage

ASH 2022 Results From Phase III BMT CTN 1703: Post-Transplant Cyclop…

Feat. S. Holtan
18:18
SOHO 2023 Eleventh Annual Meeting

SOHO 2023: Emerging BCL2 Inhibitors

Feat. M. Ann Anderson
05:04
ASH 2022 Conference Coverage

ASH 2022 Phase III SUNMO Trial: Evaluating the Efficacy & Safety…

Feat. J. Westin
17:36
SOHO 2023 Eleventh Annual Meeting

SOHO 2023: The Emergence of Bispecific Antibodies in Aggressive B-Ce…

Feat. M. Hutchings
11:12
SOHO 2023 Eleventh Annual Meeting

SOHO 2023 Next Questions: Indolent B-Cell Lymphoma

Feat. L. Nastoupil
14:36
Penn Medicine's 2024 Updates in Care of the Hematologic Malignancies Patient

The Latest Data on New Therapies in FL and MZL

Feat. J. Carter
12:43
SOHO 2023 Eleventh Annual Meeting

SOHO 2023: Bispecific Antibodies or CAR T-Cells for Indolent B-NHL?

Feat. C. Jacobson
13:22
SOHO 2022 Tenth Annual Meeting

SOHO 2022: The Next Generation of Novel Agents in Development for Ag…

Feat. J. Westin
38:55
Indy Hematology Review

Managing Indolent and Mantle Cell Lymphomas With Targeted and Cellul…

Feat. G. Salles